JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study

  • 0Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
Intestinal Research +

|

July 14, 2025

|

July 14, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Early remission with vedolizumab (VDZ) in ulcerative colitis (UC) patients predicts long-term success. Week 2 remission is a key indicator for guiding maintenance treatment strategies in UC.

Area Of Science

  • Gastroenterology
  • Immunology
  • Pharmacology

Background

  • Vedolizumab (VDZ), a gut-selective monoclonal antibody, is used for ulcerative colitis (UC) treatment.
  • Currently, no established biomarkers predict long-term remission with VDZ therapy.
  • Early remission assessment could optimize maintenance treatment strategies.

Purpose Of The Study

  • To evaluate if week 2 remission predicts week 54 remission in UC patients treated with VDZ.
  • To identify predictors of early (week 2) and long-term (week 54) remission.

Main Methods

  • Retrospective observational chart review of UC patients initiating VDZ in Japan (Dec 2018-Feb 2020).
  • Assessed 14- and 54-week remission rates based on early response.
  • Used logistic regression to identify predictive factors for week 2 and week 54 remission.

Main Results

  • 332 UC patients included; biologic-naïve patients showed higher week 2 remission rates (36.9% vs. 28.2%).
  • Week 54 remission rates differed significantly between early responders and non-responders.
  • Week 2 remission predicted week 54 remission (OR 2.41; P=0.0052).
  • Predictors for week 2 remission included male sex, no prior anti-TNFα exposure, and mild endoscopic findings.
  • Week 54 remission was associated with week 2 remission and no tacrolimus use.

Conclusions

  • Week 2 remission is a significant predictor of week 54 remission in UC patients receiving VDZ.
  • Early assessment of VDZ efficacy at week 2 can inform clinical decision-making for UC treatment.

Keywords:

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD 01:29

239

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents 01:29

272

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids 01:21

204

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF 01:24

237

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Inflammatory Bowel Disease IV: Pharmacological Management 01:29

198

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Inflammatory Bowel Disease I: Ulcerative Colitis 01:27

332

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...